AG真人官方

Aethlon Medical, Inc. (AEMD) filed an amended S-1 registration statement describing a best-efforts offering of up to 4,566,210 shares of common stock and related pre-funded warrants and placement-agent warrants. The company discloses it has no material revenue, a history of significant operating losses, and substantial doubt about its ability to continue as a going concern for 12 months without additional financing. Placement agent compensation includes a cash fee equal to 6.25% of gross proceeds and warrants equal to 4.0% of shares issued. Net tangible book value was $1.32 per share as of June 30, 2025. The filing highlights material dilution risks from outstanding warrants and reserved shares, regulatory and FDA compliance risks for its Hemopurifier and related technologies, numerous owned and pending patents across jurisdictions, and a 60-day lock-up by officers and directors.

Aethlon Medical, Inc. (AEMD) is filing an S-1 registration statement that covers a Company Offering and a resale by Selling Securityholders of up to 1,550,000 shares issuable upon exercise of inducement warrants. The prospectus discloses a history of significant operating losses, no current revenue streams, and expresses substantial doubt about the company鈥檚 ability to continue as a going concern for 12 months following its most recent financial statements. The offering is on a best-efforts basis with no minimum, so proceeds are presently undeterminable. Placement-agent compensation includes a 6.5% cash fee on gross proceeds and warrants equal to 4.0% of shares issued in the offering. Pre-funded warrants include a 4.99% beneficial ownership exercise blocker (expandable to 9.99% after notice). The company lists a broad patent portfolio across the U.S., Europe, Asia, Canada and other jurisdictions and states proceeds, if received, would be used for general corporate purposes, R&D, clinical trials and working capital.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 185,000 shares of Aethlon Medical Inc. Together they hold 7.16% of the outstanding common stock, based on 2,585,316 shares outstanding as of June 24, 2025. Armistice Capital is the investment manager of the Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises shared voting and dispositive power over the securities. Mr. Boyd, as managing member, is reported to share those voting and disposition rights. The Master Fund disclaims direct beneficial ownership due to its investment management agreement.

Aethlon Medical, Inc. (AEMD) reported a quarterly net loss of $1.76 million for the three months ended June 30, 2025, an improvement from $2.57 million a year earlier driven by lower payroll and professional fees. Revenue remained $0; operating expenses declined to $1.79 million from $2.62 million as headcount-related costs, severance and certain consulting fees decreased. Basic and diluted loss per share was ($0.85) versus ($2.76) in the prior year on a larger weighted-average share base of 2,076,416 shares.

Balance sheet highlights: cash and cash equivalents were $3.77 million, total assets $5.31 million, total liabilities $1.88 million, and stockholders' equity $3.42 million. Working capital fell to $2.42 million from $4.05 million at March 31, 2025. Management discloses substantial doubt about the company's ability to continue as a going concern and expects existing cash to be insufficient to fund operations for at least twelve months without additional financing.

Clinical and operational updates stated explicitly: the Hemopurifier phase 1 oncology trial is active at three Australian sites, three participants were treated in cohort 1 with no DSMB safety concerns, cohort 2 enrollment is open, the planned India trial (CDSCO-approved July 7, 2025) was cancelled to conserve resources, and a preprint reported >98% removal of platelet-derived EVs in an ex-vivo study. The company effected a 1-for-8 reverse stock split effective June 9, 2025 and maintains an open IDE for viral indications.

Aethlon Medical (Nasdaq:AEMD) filed a Form 8-K to furnish its press release announcing financial results for the quarter ended March 31, 2025. Reported under Items 2.02 and 7.01, the filing attaches the release as Exhibit 99.1 and states the information is provided under Regulation FD and not deemed 鈥渇iled鈥� for Exchange Act purposes. No detailed financial metrics, guidance, or strategic updates are included in the 8-K itself. Aside from furnishing the exhibit, the report discloses no material events likely to affect the company鈥檚 operating outlook or capital structure. Investors must review Exhibit 99.1 for the actual results.